CLN2 disease
Scope
Date
~
-
Bio & Pharma
Samsung Bioepis’ SB12 shows same clinical effects as Alexion’s Soliris
Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, said its SB12, a proposed biosimilar to Alexion Pharmaceuticals Inc.’s rare bl...
Jun 14, 2022 (Gmt+09:00)
language -
Pharmaceuticals
ABL Bio in $1.06 bn deal with Sanofi for Parkinson's disease treatment
South Korea’s ABL Bio Inc. has signed a $1.06 billion contract to license out its technology for a Parkinson's disease treatment candidate t...
Jan 12, 2022 (Gmt+09:00)
-
Pharmaceuticals
High-priced drugs add to pressure for Korea's healthcare reform
A number of new rare disease treatments, approved in South Korea over the past year, are still unaffordable for the public because of their price ta...
Sep 15, 2021 (Gmt+09:00)
-
Pharmaceuticals
TiumBio acquires stake in SK Plasma to beef up R&D for rare diseases
South Korea-based biopharmaceutical company TiumBio is set to acquire 30 billion won ($26 million) worth of shares in SK Plasma, a blood product com...
Jul 28, 2021 (Gmt+09:00)
-
Pharmaceuticals
SK Biopharm aims to make it to global top 10 healthcare firms by 2030
South Korea’s SK Biopharmaceuticals Co. said on Friday it aspires to become one of the world’s top 10 healthcare companies by 2030 with ...
Jul 02, 2021 (Gmt+09:00)
-
Bio
Celltrion to co-develop pill-type autoimmune disease drug with UK startup
Biosimilar maker Celltrion Inc. has agreed to develop a tablet-type treatment for autoimmune diseases jointly with the UK biotech startup Intract Phar...
Aug 20, 2020 (Gmt+09:00)